Abstract | BACKGROUND: CASE REPORT: A 45-year-old woman had complicated Crohn's disease with multiple fistulae and only 1 m of residual small bowel. She had been receiving TPN for 2.5 years when she developed cholestasis which worsened despite adjustments to her TPN regimen. Infliximab, an anti- TNFalpha antibody, was given with the aim of treating an enterocutaneous fistula, but it also produced a marked biochemical and histological improvement in the TPN-related cholestasis. CONCLUSIONS:
|
Authors | Ewan H Forrest, K A Oien, S Dickson, D Galloway, P R Mills |
Journal | Liver
(Liver)
Vol. 22
Issue 4
Pg. 317-20
(Aug 2002)
ISSN: 0106-9543 [Print] Denmark |
PMID | 12296965
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antirheumatic Agents
- Tumor Necrosis Factor-alpha
- Infliximab
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antirheumatic Agents
(toxicity)
- Cholestasis
(drug therapy, etiology)
- Crohn Disease
(complications, therapy)
- Female
- Humans
- Infliximab
- Middle Aged
- Parenteral Nutrition, Total
(adverse effects)
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(therapeutic use)
|